Real-World Experience with FcRn Inhibitors Efgartigimod and Rozanolixizumab in Myasthenia Gravis: Administration in Multiple Cycles and Transition from Intravenous to Subcutaneous Formulation
FcRn inhibitors were effective and safe in patients with generalized MG, but their efficacy may depend on the disease activity during treatment. The transition from the intravenous formulation to more convenient subcutaneous formulations was successful, indicating the likely growth of future demand for subcutaneous formulations.
Authors
- Motohiro Yukitake
- Makoto Eriguchi (ORCID: https://orcid.org/0000-0002-8275-2331)
- Kohei Suzuyama (ORCID: https://orcid.org/0000-0002-6077-0758)
- Manabu Iwasaki
- Chika Shichijo
- Yuki Hoshino (ORCID: https://orcid.org/0009-0003-6778-2764)
- Toshihiro Ide (ORCID: https://orcid.org/0000-0002-3458-7159)
- Haruki Koike (ORCID: https://orcid.org/0000-0002-4612-3183)
- Hiroshi Takashima (ORCID: https://orcid.org/0000-0003-0989-6141)
- Keisuke Tsumura
- Masaaki Yoshikawa (ORCID: https://orcid.org/0000-0001-7580-786X)
- Koya Tanaka
- Yukako Inoue
Institutions
- Saga University (JP)
- Red Cross Hospital (GR)
- Saga-Ken Medical Centre Koseikan (JP)
- Shirasagi Hospital (JP)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1007/s40120-025-00748-4
- Citations
- 4
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 5.56